Corrigendum

Corrigendum to “Considerations for the Treatment of Oesophageal Cancer with Radiotherapy During the COVID-19 Pandemic” [Clin Oncol 32 (2020) 354–357]

C.M. Jones *,†, M. Hawkins §, S. Mukherjee ¶, G. Radhakrishna ||, T. Crosby **

* School of Molecular & Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK
† Radiotherapy Research Group, Leeds Institute of Medical Research at St James’s, Faculty of Medicine & Health, University of Leeds, Leeds, UK
§ Leeds Cancer Centre, The Leeds Teaching Hospitals NHS Trust, Leeds, UK
¶ Department of Medical Physics & Biomedical Engineering, University College London, London, UK
|| CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK
|| Christie Hospital, The Christie NHS Foundation Trust, Manchester, UK
** Velindre Cancer Centre, Cardiff, UK

The author regrets that in Table 1 of this manuscript, the suggested dose for hypofractionated radiotherapy was erroneously described as 55 Gy/10 fractions for tumours of up to 10cm in length. In keeping with the main text of the article, which is correct, this should have described a recommended dose of 50-55 Gy/20 fractions.